Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

Encouraging Results Prompted Phase 2 Study Now Underway at Nine Centers

SAN DIEGO, Calif., April 16, 2007 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today presented long term follow-up data from a Phase 1 clinical trial of CERE-120, a gene therapy product in development for the treatment of Parkinson's disease, demonstrating a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in this study. The 12-month results were presented today by Philip Starr, M.D., Ph.D., associate professor of neurosurgery at the University of California, San Francisco at the American Association of Neurological Surgeons (AANS) annual meeting in Washington D.C. These data were also highlighted by the AANS in a specific CERE-120 press release issued by the Association.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco and Rush University Medical Center in Chicago. All 12 patients enrolled in the study underwent stereotactic neurosurgery to deliver CERE-120 into their putamen -- a region of the brain affected by the degeneration of neurons in Parkinson's disease.

CERE-120 was delivered at two different doses, and patients receiving the low dose demonstrated approximately 36 percent improvement in UPDRS motor "off" scores by nine months and patients receiving the four-fold higher dose showed a similar effect three months sooner. This statistically significant, 36 percent improvement was maintained in both groups at the 12-month mark, the final follow-up time point in the study. Patients also demonstrated a 50 percent reduction in hours of "
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:9/29/2014)... , Sept. 29, 2014  Guerbet, a ... medical imaging, has received a Drug Shortage Assistance ... for its assistance in preventing or alleviating a ... for its efforts related to the shortage of ... drug application, submitting several post-approval supplements to restart ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
(Date:9/29/2014)... PERTH AMBOY, N.J. , Sept. 29, 2014 /PRNewswire/ ... to accept customer service inquiries via Twitter, the social ... able to Tweet inquiries and issues related to customer ... Twitter,s ubiquitous use and its accessibility from ... Bay Medical Center to better serve its patients and ...
Breaking Medicine Technology:Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3@myrbmc: Healthcare Customer Service Support in 140 Characters or Less 2
... Drug Administration (FDA) approval of Differin® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne. Differin ... ... , ... ...
... legislation passed by the U.S. House of Representatives will improve community pharmacists, ability to improve patient outcomes and reduce costs, the National Community Pharmacists Association (NCPA) said today. , ... , ... ... ...
Cached Medicine Technology:Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 2Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 3Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 4Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 5Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 6Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 7NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill 2NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill 3
(Date:9/29/2014)... Florida (PRWEB) September 30, 2014 Foundations ... proud to announce the start of its 40th national ... Glenn Greenwald as a featured keynote speaker at the ... leading experts specializing in the fields of addiction and ... West Palm Beach, Fla., September 29 – October 2, ...
(Date:9/29/2014)... Morristown, NJ (PRWEB) September 30, 2014 ... their members at their annual picnic to celebrate their strides ... Thursday, August 28th at 6:00 p.m. at their Morristown office. ... its inception in 2012 and is a place where patients ... family members. At the picnic food and activities were enjoyed ...
(Date:9/29/2014)... September 30, 2014 NAPW ... 2014 Professional Woman of the Year. Dr. Mondloch is ... and preventative medicine As the largest, most-recognized networking organization ... industry and profession, the National Association of Professional Women ... members and nearly 300 Local Chapters. , “Initially my ...
(Date:9/29/2014)... 29, 2014 Park Avenue Dental, a ... Dr. Michael A. Sherman who has dedicated his career ... care, has announced its inclusion in the Patient Connect ... patients access to private accounts so that they may ... Further, the system also allows patients to request appointments, ...
(Date:9/29/2014)... Washington, D.C. September 30, 2014 (PRWEB) September 29, 2014 ... enable devices like smartphones, tablets and laptops provides the ... for all ages, from youth to adult, to raise ... to obtain professional licensure, or to obtain certification in ... needs an educated workforce to compete effectively and at ...
Breaking Medicine News(10 mins):Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Local Brain Tumor Foundation, ANS Center of Hope, Celebrates its Brain Cancer Patients 2Health News:National Association of Professional Women Announces Victoria J. Mondloch, M.D., Family Medicine and Women's Health, a 2014 Professional Woman of the Year 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 3Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 2Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 3
... cancer should not be a stimulation to be relieved ... infection//. ,This arises due to its treatment ... with the general population. ,According to the study ... colorectal cancer, lung cancer, renal cancer, thyroid cancer, soft ...
... has been found to be effective in treatment of ... benefited from vitamin treatment as found by researchers from ... intervention wherein patients not responsive to steroid treatment after ... ,Professor Tak Lee, Director of the MRC-Asthma UK ...
... Court in Brisbane, Australia, has convicted 37-year-old Mark Kenneth Reid ... partner through unprotected sex//. Reid had been HIV positive since ... has been sentenced to 10 year’s imprisonment by the court. ... ,Kenneth Reid contended that he had informed his ...
... sleeping pills for treatment of insomnia has no doubt prompted ... have the best clinical// benefits according to a new review ... be inferred form the statement ‘Early to bed, early to ... of them who are deprived this wonderful gift, there are ...
... project stem cell requirements for the establishment of a therapeutic ... cell lines would// be required to support the functioning on ... United States represent countries where intensive stem cell research is ... established in Britain in the year 2004. Over the next ...
... regarding safe sex and prevention of HIV/AIDS in the ... unwillingness regarding using a condom amongst visitors to the ... Prevention and Control Society (WBSACS), with an aim of ... to distribute female condoms free of cost. The above-mentioned ...
Cached Medicine News:Health News:Asthma an be treated with Vitamin supplement intervention 2Health News:Newer Generation Sleeping Pills Lack Superior Performance 2Health News:Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines 2Health News:Safety Of Indian Sex Workers At Risk Due To Poor Condom Usage 2
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... 2 500ML Sterile H 2 O, ... ease of use. You can obtain heated and ... FIO 2 . We offer a wide selection ... sodium chloride inhalation, USP; and 0.9% sodium chloride ...
Nebulizer Custom Misty with Aerosol Mask...
... One device provides both low FIO2 ... single gas source , Reduce supply ... of SKUs dedicated to nebulizers , ... double or wye set ups , ...
Medicine Products: